PURPOSE: The development of health-related genomic tests is decentralized and dynamic, involving government, academic, and commercial entities. Consequently, it is not easy to determine which tests are in development, currently available, or discontinued. We developed and assessed the usefulness of a systematic approach to identifying new genomic tests on the Internet. METHODS: We devised targeted queries of Web pages, newspaper articles, and blogs (Google Alerts) to identify new genomic tests. We finalized search and review procedures during a pilot phase that ended in March 2010. Queries continue to run daily and are compiled weekly; selected data are indexed in an online database, the Genomic Applications in Practice and Prevention Finder. RESULTS: After the pilot phase, our scan detected approximately two to three new genomic tests per week. Nearly two thirds of all tests (122/188, 65%) were related to cancer; only 6% were related to hereditary disorders. Although 88 (47%) of the tests, including 2 marketed directly to consumers, were commercially available, only 12 (6%) claimed United States Food and Drug Administration licensure. CONCLUSION: Systematic surveillance of the Internet provides information about genomic tests that can be used in combination with other resources to evaluate genomic tests. The Genomic Applications in Practice and Prevention Finder makes this information accessible to a wide group of stakeholders.
PURPOSE: The development of health-related genomic tests is decentralized and dynamic, involving government, academic, and commercial entities. Consequently, it is not easy to determine which tests are in development, currently available, or discontinued. We developed and assessed the usefulness of a systematic approach to identifying new genomic tests on the Internet. METHODS: We devised targeted queries of Web pages, newspaper articles, and blogs (Google Alerts) to identify new genomic tests. We finalized search and review procedures during a pilot phase that ended in March 2010. Queries continue to run daily and are compiled weekly; selected data are indexed in an online database, the Genomic Applications in Practice and Prevention Finder. RESULTS: After the pilot phase, our scan detected approximately two to three new genomic tests per week. Nearly two thirds of all tests (122/188, 65%) were related to cancer; only 6% were related to hereditary disorders. Although 88 (47%) of the tests, including 2 marketed directly to consumers, were commercially available, only 12 (6%) claimed United States Food and Drug Administration licensure. CONCLUSION: Systematic surveillance of the Internet provides information about genomic tests that can be used in combination with other resources to evaluate genomic tests. The Genomic Applications in Practice and Prevention Finder makes this information accessible to a wide group of stakeholders.
Authors: Muin J Khoury; Ralph J Coates; Mary L Fennell; Russell E Glasgow; Maren T Scheuner; Sheri D Schully; Marc S Williams; Steven B Clauser Journal: J Natl Cancer Inst Monogr Date: 2012-05
Authors: Rahber Thariani; William Wong; Josh J Carlson; Louis Garrison; Scott Ramsey; Patricia A Deverka; Laura Esmail; Sneha Rangarao; Carolyn J Hoban; Laurence H Baker; David L Veenstra Journal: Med Care Date: 2012-05 Impact factor: 2.983
Authors: Carlie A LaLone; Gerald T Ankley; Scott E Belanger; Michelle R Embry; Geoff Hodges; Dries Knapen; Sharon Munn; Edward J Perkins; Murray A Rudd; Daniel L Villeneuve; Maurice Whelan; Catherine Willett; Xiaowei Zhang; Markus Hecker Journal: Environ Toxicol Chem Date: 2017-06 Impact factor: 3.742
Authors: Vural Özdemir; Kamal F Badr; Edward S Dove; Laszlo Endrenyi; Christy Jo Geraci; Peter J Hotez; Djims Milius; Maria Neves-Pereira; Tikki Pang; Charles N Rotimi; Ramzi Sabra; Christineh N Sarkissian; Sanjeeva Srivastava; Hesther Tims; Nathalie K Zgheib; Ilona Kickbusch Journal: OMICS Date: 2013-04
Authors: W D Dotson; M P Douglas; K Kolor; A C Stewart; M S Bowen; M Gwinn; A Wulf; H M Anders; C Q Chang; M Clyne; T K Lam; S D Schully; M Marrone; W G Feero; M J Khoury Journal: Clin Pharmacol Ther Date: 2014-02-19 Impact factor: 6.875
Authors: Muin J Khoury; Steven B Clauser; Andrew N Freedman; Elizabeth M Gillanders; Russ E Glasgow; William M P Klein; Sheri D Schully Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-27 Impact factor: 4.254
Authors: Dana C Crawford; Robert Goodloe; Eric Farber-Eger; Jonathan Boston; Sarah A Pendergrass; Jonathan L Haines; Marylyn D Ritchie; William S Bush Journal: Hum Hered Date: 2015-07-28 Impact factor: 0.444
Authors: Naoko I Simonds; Muin J Khoury; Sheri D Schully; Katrina Armstrong; Wendy F Cohn; David A Fenstermacher; Geoffrey S Ginsburg; Katrina A B Goddard; William A Knaus; Gary H Lyman; Scott D Ramsey; Jianfeng Xu; Andrew N Freedman Journal: J Natl Cancer Inst Date: 2013-05-09 Impact factor: 13.506